Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS203
- Development stage
- Preclinical
- Lead developer
- Genscend Biopharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GS203 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Genscend Biopharmaceutical as a biosimilar of trastuzumab deruxtecan (Enhertu). It consists of a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) conjugated to a topoisomerase I inhibitor payload (deruxtecan) via a cleavable linker. GS203 is designed to target and deliver its cytotoxic payload to HER2-expressing tumor cells, inducing DNA damage and apoptosis. It is currently in preclinical/IND-enabling development for the treatment of breast cancer and other HER2-expressing solid tumors.
- Other names
- Fam-trastuzumab deruxtecan-NXKI Biosimilartrastuzumab deruxtecan biosimilar
02
Targets
TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on GS203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS203.